Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA29 Tofacitinib
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Tofacitinib
D09783 Tofacitinib citrate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D09783 Tofacitinib citrate (JAN/USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG00742 Tofacitinib
D09783 Tofacitinib citrate
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG00742 Tofacitinib
D09783 Tofacitinib citrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00742 Tofacitinib
D09783 Tofacitinib citrate
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D09783 Tofacitinib citrate
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D09783 Tofacitinib citrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
JAK2
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
JAK3
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
TYK2
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09783
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09783
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09783
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09783
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09783
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG00742 Tofacitinib
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG00742 Tofacitinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00742 Tofacitinib